<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Avapritinib: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Avapritinib: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Avapritinib: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="126557" href="/d/html/126557.html" rel="external">see "Avapritinib: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F54012717"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Ayvakit</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F54007187"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antineoplastic Agent, KIT Inhibitor;</li>
<li>
                        Antineoplastic Agent, PDGFR-alpha Blocker;</li>
<li>
                        Antineoplastic Agent, Tyrosine Kinase Inhibitor</li></ul></div>
<div class="block doa drugH1Div" id="F54018740"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Note: </b>Avapritinib is associated with a moderate or high emetic potential; antiemetics may be recommended to prevent nausea and vomiting (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32658626']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32658626'])">Ref</a></span>). For the treatment of advanced systemic mastocytosis or indolent systemic mastocytosis, use is not recommended if platelet count is &lt;50,000/mm<sup>3</sup>.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f82049de-3d4e-4e1a-8119-4c18fc5e35b4">Gastrointestinal stromal tumor, unresectable or metastatic, with a PDGFRA exon 18 mutation</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Gastrointestinal stromal tumor, unresectable or metastatic, with a PDGFRA exon 18 mutation:</b>
<b>Oral:</b> 300 mg once daily until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32615108']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32615108'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="34feb839-26bb-4e7c-b1d3-3f8cf5712bbd">Systemic mastocytosis, advanced</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Systemic mastocytosis, advanced:</b>
<b>Oral:</b> 200 mg once daily until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34873347','lexi-content-ref-34873345','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34873347','lexi-content-ref-34873345','lexi-content-ref-Manu.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ec9cdd96-2220-4ff9-a6d7-39481afdfb49">Systemic mastocytosis, indolent</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Systemic mastocytosis, indolent:</b>
<b>Oral:</b> 25 mg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34663404','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34663404','lexi-content-ref-Manu.1'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<i>Missed/vomited doses:</i> Do not make up for a missed dose within 8 hours of the next scheduled dose. If vomiting occurs, do not repeat dose; resume dosing with the next scheduled daily dose.</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug Interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug Interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F54018742"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b> Note: </b>Kidney function estimated by Cockcroft-Gault equation.</p>
<p style="text-indent:-2em;margin-left:2em;">CrCl 30 to 89 mL/minute: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">CrCl ≤29 mL/minute: There are no dosage adjustments provided in the manufacturer's labeling (a recommended dose has not been established).</p>
<p style="text-indent:-2em;margin-left:2em;">End-stage renal disease: There are no dosage adjustments provided in the manufacturer's labeling (a recommended dose has not been established).</p></div>
<div class="block doha drugH1Div" id="F54018743"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Mild (total bilirubin ≤ ULN and AST &gt; ULN <b>or</b> total bilirubin 1 to 1.5 times ULN and any AST) or moderate (total bilirubin &gt;1.5 to 3 times ULN and any AST) impairment: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">Severe impairment (Child-Pugh class C): Initial dose:</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal stromal tumor: <b>Oral: </b>200 mg once daily.</p>
<p style="text-indent:-2em;margin-left:4em;">Systemic mastocytosis, advanced: <b>Oral: </b>100 mg once daily.</p>
<p style="text-indent:-2em;margin-left:4em;">Systemic mastocytosis, indolent: <b>Oral: </b>25 mg every other day.</p></div>
<div class="block dot drugH1Div" id="F54018744"><span class="drugH1">Dosing: Adjustment for Toxicity: Adult</span>
<table border="1" frame="border" rules="all">
<caption style="text-align:center;">
<b>Recommended Avapritinib Dosage Reduction Levels<sup>a</sup></b></caption>
<colgroup><col/>
<col/>
<col/>
</colgroup><thead>
<tr>
<th align="center"></th>
<th align="center">
<p style="text-indent:0em;">GIST</p></th>
<th align="center">
<p style="text-indent:0em;">AdvSM</p></th></tr></thead>
<tfoot valign="top">
<tr>
<td align="center" colspan="3">
<p style="text-indent:0em;">
<sup>a</sup> GIST = gastrointestinal stromal tumor; AdvSM = advanced systemic mastocytosis.</p></td></tr></tfoot>
<tbody valign="middle">
<tr>
<td align="center">
<p style="text-indent:0em;">Initial (usual) dose</p></td>
<td align="center">
<p style="text-indent:0em;">300 mg once daily</p></td>
<td align="center">
<p style="text-indent:0em;">200 mg once daily</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">First dose reduction</p></td>
<td align="center">
<p style="text-indent:0em;">200 mg once daily</p></td>
<td align="center">
<p style="text-indent:0em;">100 mg once daily</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Second dose reduction</p></td>
<td align="center">
<p style="text-indent:0em;">100 mg once daily</p></td>
<td align="center">
<p style="text-indent:0em;">50 mg once daily</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Third dose reduction</p></td>
<td align="center">
<p style="text-indent:0em;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;">25 mg once daily</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">If further dose reductions are necessary</p></td>
<td align="center">
<p style="text-indent:0em;">Permanently discontinue avapritinib in patients with GIST unable to tolerate 100 mg once daily.</p></td>
<td align="center">
<p style="text-indent:0em;">Permanently discontinue avapritinib in patients with AdvSM unable to tolerate 25 mg once daily.</p></td></tr></tbody></table>
<table border="1" frame="border" rules="all">
<caption style="text-align:center;">
<b>Avapritinib Recommended Dose Modifications for Adverse Reactions<sup>a</sup></b></caption>
<colgroup><col/>
<col/>
<col/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;">Adverse reaction</p></th>
<th align="center">
<p style="text-indent:0em;">Severity</p></th>
<th align="center">
<p style="text-indent:0em;">Dose modification</p></th></tr></thead>
<tfoot valign="top">
<tr>
<td align="center" colspan="3">
<p style="text-indent:0em;">
<sup>a</sup> GIST = gastrointestinal stromal tumor; AdvSM = advanced systemic mastocytosis.</p></td></tr></tfoot>
<tbody valign="middle">
<tr>
<td align="center" colspan="3">
<p style="text-indent:0em;">
<b>GIST or AdvSM</b></p></td></tr>
<tr>
<td align="center" rowspan="3">
<p style="text-indent:0em;">Cognitive effects</p></td>
<td align="center">
<p style="text-indent:0em;">Grade 1</p></td>
<td align="center">
<p style="text-indent:0em;">Continue avapritinib at the same or a reduced dose or withhold dose until improvement to baseline or resolution; resume at the same or at a reduced dose.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Grade 2 or 3</p></td>
<td align="center">
<p style="text-indent:0em;">Withhold avapritinib until improvement to baseline, grade 1, or resolution; resume at the same or at a reduced dose.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Grade 4</p></td>
<td align="center">
<p style="text-indent:0em;">Permanently discontinue avapritinib.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Intracranial hemorrhage</p></td>
<td align="center">
<p style="text-indent:0em;">Any grade</p></td>
<td align="center">
<p style="text-indent:0em;">Permanently discontinue avapritinib.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Other toxicity</p></td>
<td align="center">
<p style="text-indent:0em;">Grade 3 or 4</p></td>
<td align="center">
<p style="text-indent:0em;">Withhold avapritinib until improvement to ≤ grade 2; resume at the same or at a reduced dose per clinical assessment.</p></td></tr>
<tr>
<td align="center" colspan="3">
<p style="text-indent:0em;">
<b>AdvSM</b></p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Thrombocytopenia</p></td>
<td align="center">
<p style="text-indent:0em;">Platelets &lt;50,000/mm<sup>3</sup></p></td>
<td align="center">
<p style="text-indent:0em;">Interrupt avapritinib until platelets are ≥50,000/mm<sup>3</sup>, then resume at a reduced dose. Consider platelet support if platelets do not recover to &gt;50,000/mm<sup>3</sup>.</p></td></tr></tbody></table></div>
<div class="block doe drugH1Div" id="F54018741"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block arsc drugH1Div" id="F54986937"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Cognitive and other CNS effects</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Cognitive effects are common with use including <b>cognitive dysfunction</b> (eg, <b>memory impairment,</b>
<b>confusion</b>, <b>disturbance in attention,</b>
<b>mental status changes,</b>
<b>amnesia</b> [including <b>retrograde amnesia</b>], <b>encephalopathy</b>, <b>dementia,</b>
<b>abnormality in thinking</b>). Other CNS effects include <b>dizziness</b>, <b>fatigue</b>, and <b>speech disturbance</b>. Cognitive and other CNS effects are typically mild to moderate; however, severe effects (≥ grade 3) may occur, particularly cognitive dysfunction and fatigue. Memory impairment is the most frequent type of cognitive dysfunction reported. Most cognitive and other CNS effects appear to be reversible following dose reductions or short interruptions (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32100250','lexi-content-ref-32462367','lexi-content-ref-31372066','lexi-content-ref-32453031']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32100250','lexi-content-ref-32462367','lexi-content-ref-31372066','lexi-content-ref-32453031'])">Ref</a></span>); however, some adverse reactions may require discontinuation.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Varied; median time to onset of the first cognitive effect was ~9 weeks (range: 1 day to 4 years).</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Edema</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Various types of <b>edema</b> (eg,<b> facial edema</b>,<b> peripheral edema, </b>generalized edema) are commonly reported. <b>Periorbital edema</b>, in particular, is associated with use and may be severe (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32100250','lexi-content-ref-31033566','lexi-content-ref-32462367','lexi-content-ref-31372066']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32100250','lexi-content-ref-31033566','lexi-content-ref-32462367','lexi-content-ref-31372066'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">GI effects</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Abdominal pain</b>,<b> constipation</b>,<b> decreased appetite, diarrhea, nausea</b>, and<b> vomiting </b>are common; GI events are usually grade 1 and 2, although may sometimes be severe. Avapritinib is associated with a moderate emetic potential.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Intracranial hemorrhage</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Intracranial hemorrhage</b>, including <b>subdural hematoma</b> and <b>cerebral hemorrhage</b>, has been infrequently observed with use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32100250']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32100250'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Delayed; onset of intracranial hemorrhage ranged from ~2 to 19 months after initiation.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">• History of vascular aneurysm, intracranial hemorrhage, or cerebrovascular accident within the prior year</p>
<p style="text-indent:-2em;margin-left:6em;">• Concomitant use of anticoagulants</p>
<p style="text-indent:-2em;margin-left:6em;">• Thrombocytopenia</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Myelosuppression</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Decreased platelet count</b>, <b>decreased</b>
<b>neutrophils,</b> and <b>leukopenia </b>are common and may be severe. <b>Anemia</b> is also frequently observed and may be severe (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31372066','lexi-content-ref-32453031']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31372066','lexi-content-ref-32453031'])">Ref</a></span>). Decreased platelet count is generally reversible following dose reduction or therapy interruption.</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F54012941"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Incidence of adverse reactions include unapproved dosing regimens. Reported adverse reactions are for adults.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Edema (72% to 79%; including facial edema [7%], periorbital edema [13% to 43%], peripheral edema [12%], and pharyngeal edema) (Farag 2020, Gilreath 2019), flushing (4% to 11%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Alopecia (9% to 13%), hair discoloration (6% to 21%), skin rash (6% to 23%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Decreased serum albumin (15% to 31%), decreased serum calcium (50%), decreased serum magnesium (14% to 29%), decreased serum phosphate (9% to 49%), decreased serum potassium (26% to 34%), decreased serum sodium (18% to 28%), increased serum potassium (11%), weight loss (13%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (14% to 31%; severe abdominal pain: 3%), ageusia (≤15%), constipation (11% to 23%), decreased appetite (8% to 38%), diarrhea (28% to 37%; grades ≥3: 1% to 5%), dysgeusia (≤15%), dyspepsia (16%), nausea (24% to 64%; grades ≥3: 1% to 3%), vomiting (18% to 38%; grades ≥3: 2% to 3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Decreased neutrophils (43% to 54%; grades ≥3: 6% to 25%), decreased platelet count (27% to 64%; grades ≥3: &lt;21%), increased INR (24%; grades ≥3: &lt;1%), leukopenia (62%; grades ≥3: 5%), lymphocytopenia (34%: grades ≥3: 11%), prolonged partial thromboplastin time (13% to 14%; grades ≥3: 1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum alanine aminotransferase (18% to 19%), increased serum alkaline phosphatase (6% to 24%), increased serum aspartate aminotransferase (38% to 51%), increased serum bilirubin (41% to 69%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Asthenia (≤61%), cognitive dysfunction (including disturbance in attention, mental status changes, dementia, abnormality in thinking: 8% to 48%; grades 3/4: ≤5%), dizziness (13% to 22%), fatigue (≤61%; grades ≥3: ≤9%), headache (15% to 17%), memory impairment (26% to 29%) (Farag 2020, Martin-Broto 2020), mood disorder (including agitation, anxiety, depression, dysphoria, irritability, nervousness, personality changes, suicidal ideation: 13%), sleep disorder (16%)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Increased lacrimation (9% to 33%)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Increased serum creatinine (20% to 29%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Dyspnea (9% to 17%), epistaxis (11%), pleural effusion (3% to 12%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (14%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Heart failure (1% to 3%), hypertension (4% to 8%), hypotension (4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Palmar-plantar erythrodysesthesia (1%), pruritus (8%), skin photosensitivity (3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hot flash (3%), hyperthyroidism (≤3%), hypothyroidism (≤3%), thyroid disease (3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Cholelithiasis (1%), gastrointestinal hemorrhage (1% to 2%), intestinal perforation (1% to 2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Urinary tract infection (6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Anemia (5% to 9%), hematoma (6%; including pelvic hematoma), hemorrhage (5%), lymphocytosis (10%), tumor hemorrhage (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Ascites (5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Herpes zoster infection (3%), sepsis (3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Amnesia (including retrograde amnesia: 3%), confusion (6%), drowsiness (2%), encephalopathy (2%), insomnia (6%), intracranial hemorrhage (1% to 3%), speech disturbance (2%), subdural hematoma (4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia (10%), limb pain (6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Acute kidney injury (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Cough (3%), pneumonia (1% to 3%), respiratory tract infection (8%), upper respiratory tract infection (6%)</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Testicular swelling</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Cerebral hemorrhage</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Purpuric rash (Mohammed 2022)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Hypersensitivity angiitis (Cocorocchio 2020)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Ophthalmic signs and symptoms (including corneal epithelial defect, preseptal cellulitis, and intraocular inflammation) (García Caride 2021), uveitis (Cocorocchio 2020)</p></div>
<div class="block coi drugH1Div" id="F54007190"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">There are no contraindications listed in the manufacturer's labeling.</p></div>
<div class="block war drugH1Div" id="F54018727"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Photosensitivity: Patients should limit sun exposure during and for 1 week after avapritinib treatment. Advise patients to wear protective clothing and use broad-spectrum UVA/UVB sunscreen.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues</i></b>
<b>
<i>:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Propylene glycol: Some dosage forms may contain propylene glycol; large amounts are potentially toxic and have been associated hyperosmolality, lactic acidosis, seizures, and respiratory depression; use caution (AAP 1997; Zar 2007). See manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Other warnings/precautions:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• PDGFRA exon 18 mutation: Select patients for the treatment of unresectable or metastatic gastrointestinal stromal tumor based on the presence of a PDGFRA exon 18 mutation. In a clinical study, PDGFRA exon 18 mutations were identified by local or central assessment using a polymerase chain reaction– or next-generation sequencing–based assay.</p></div>
<div class="block foc drugH1Div" id="F54012718"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Ayvakit: 25 mg, 50 mg, 100 mg, 200 mg, 300 mg</p></div>
<div class="block geq drugH1Div" id="F54012716"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F54082352"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Ayvakit Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">25 mg (per each): $1,557.16</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mg (per each): $1,557.16</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg (per each): $1,557.16</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">200 mg (per each): $1,557.16</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">300 mg (per each): $1,557.16</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block accres drugH1Div" id="F54018722"><span class="drugH1">Prescribing and Access Restrictions</span>
<p style="text-indent:0em;">Avapritinib is available through a select network of specialty pharmacies. For more information, refer to https://ayvakit.com/hcp/.</p></div>
<div class="block adm drugH1Div" id="F54018745"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Oral:</b> Administer on an empty stomach, at least 1 hour before or 2 hours after a meal. Avapritinib is associated with a moderate or high emetic potential; antiemetics may be recommended to prevent nausea and vomiting (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32658626']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32658626'])">Ref</a></span>).</p></div>
<div class="block hazard drugH1Div" id="F54018730"><span class="drugH1">Hazardous Drugs Handling Considerations</span>
<p style="text-indent:0em;">This medication is not on the NIOSH (2016) list; however, it may meet the criteria for a hazardous drug. Avapritinib may cause reproductive toxicity, teratogenicity, and has a structural or toxicity profile similar to existing hazardous agents.</p>
<p style="text-indent:0em;margin-top:2em;">Use appropriate precautions for receiving, handling, storage, preparation, dispensing, transporting, administration, and disposal. Follow NIOSH and USP 800 recommendations <b>and</b> institution-specific policies/procedures for appropriate containment strategy (NIOSH 2016; USP-NF 2020).</p>
<p style="text-indent:0em;margin-top:2em;">
<b>Note:</b> Facilities may perform risk assessment of some hazardous drugs to determine if appropriate for alternative handling and containment strategies (USP-NF 2020). Refer to institution-specific handling policies/procedures.</p></div>
<div class="block use drugH1Div" id="F54007189"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Gastrointestinal stromal tumor, unresectable or metastatic:</b> Treatment of unresectable or metastatic gastrointestinal stromal tumor harboring a PDGFRA exon 18 mutation, including PDGFRA D842V mutations in adults.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Systemic mastocytosis, advanced:</b> Treatment of advanced systemic mastocytosis (AdvSM) in adults, including aggressive systemic mastocytosis, systemic mastocytosis with an associated hematological neoplasm, and mast cell leukemia.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Systemic mastocytosis, indolent:</b> Treatment of indolent systemic mastocytosis (ISM) in adults.</p>
<p style="text-indent:-2em;margin-left:2em;">Limitations of use: Avapritinib is not recommended for the treatment of patients with AdvSM or ISM with platelet counts of &lt;50,000/mm<sup>3</sup>.</p></div>
<div class="block mst drugH1Div" id="F54018721"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:0em;margin-left:2em;">Avapritinib may be confused with acalabrutinib, afatinib, alectinib, alpelisib, amivantamab, axitinib, enasidenib, ibrutinib, imatinib, ripretinib.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">This medication is in a class the Institute for Safe Medication Practices includes among its lists of drug classes which have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F54018628"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP2C9 (minor), CYP3A4 (major), UGT1A3; <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F54018625"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alizapride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Azelastine (Nasal): May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Blonanserin: CNS Depressants may enhance the CNS depressant effect of Blonanserin.  Management: Use caution if coadministering blonanserin and CNS depressants; dose reduction of the other CNS depressant may be required. Strong CNS depressants should not be coadministered with blonanserin.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brexanolone: CNS Depressants may enhance the CNS depressant effect of Brexanolone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brimonidine (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromopride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromperidol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of other CNS depressants, and avoiding such drugs in patients at high risk of buprenorphine overuse/self-injection. Initiate buprenorphine at lower doses in patients already receiving CNS depressants.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cannabinoid-Containing Products: CNS Depressants may enhance the CNS depressant effect of Cannabinoid-Containing Products. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chlormethiazole: May enhance the CNS depressant effect of CNS Depressants. Management: Monitor closely for evidence of excessive CNS depression. The chlormethiazole labeling states that an appropriately reduced dose should be used if such a combination must be used.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chlorphenesin Carbamate: May enhance the adverse/toxic effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Moderate): May decrease the serum concentration of Avapritinib.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Strong): May decrease the serum concentration of Avapritinib.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Moderate): May increase the serum concentration of Avapritinib. Management: Avoid use of moderate CYP3A4 inhibitors with avapritinib. If this combination cannot be avoided, reduce the avapritinib dose to 100 mg daily for the treatment of GIST or to 50 mg daily for the treatment of advanced systemic mastocytosis.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Strong): May increase the serum concentration of Avapritinib.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Daridorexant: May enhance the CNS depressant effect of CNS Depressants. Management: Dose reduction of daridorexant and/or any other CNS depressant may be necessary. Use of daridorexant with alcohol is not recommended, and the use of daridorexant with any other drug to treat insomnia is not recommended.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">DexmedeTOMIDine: CNS Depressants may enhance the CNS depressant effect of DexmedeTOMIDine.  Management: Monitor for increased CNS depression during coadministration of dexmedetomidine and CNS depressants, and consider dose reductions of either agent to avoid excessive CNS depression.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Difelikefalin: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dimethindene (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Doxylamine: CNS Depressants may enhance the CNS depressant effect of Doxylamine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DroPERidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (eg, opioids, barbiturates) with concomitant use.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Esketamine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flunarizine: CNS Depressants may enhance the CNS depressant effect of Flunarizine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flunitrazepam: CNS Depressants may enhance the CNS depressant effect of Flunitrazepam.  Management: Reduce the dose of CNS depressants when combined with flunitrazepam and monitor patients for evidence of CNS depression (eg, sedation, respiratory depression). Use non-CNS depressant alternatives when available.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants. Management: Consider a decrease in the CNS depressant dose, as appropriate, when used together with hydroxyzine. Increase monitoring of signs/symptoms of CNS depression in any patient receiving hydroxyzine together with another CNS depressant.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ixabepilone: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Kava Kava: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Kratom: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lemborexant: May enhance the CNS depressant effect of CNS Depressants. Management: Dosage adjustments of lemborexant and of concomitant CNS depressants may be necessary when administered together because of potentially additive CNS depressant effects. Close monitoring for CNS depressant effects is necessary.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lisuride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lofexidine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce the usual dose of CNS depressants by 50% if starting methotrimeprazine until the dose of methotrimeprazine is stable. Monitor patient closely for evidence of CNS depression.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Metoclopramide: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">MetyroSINE: CNS Depressants may enhance the sedative effect of MetyroSINE. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Minocycline (Systemic): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nabilone: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olopatadine (Nasal): May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Opioid Agonists: CNS Depressants may enhance the CNS depressant effect of Opioid Agonists.  Management: Avoid concomitant use of opioid agonists and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Orphenadrine: CNS Depressants may enhance the CNS depressant effect of Orphenadrine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oxomemazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oxybate Salt Products: CNS Depressants may enhance the CNS depressant effect of Oxybate Salt Products.  Management: Consider alternatives to this combination when possible. If combined, dose reduction or discontinuation of one or more CNS depressants (including the oxybate salt product) should be considered. Interrupt oxybate salt treatment during short-term opioid use<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">OxyCODONE: CNS Depressants may enhance the CNS depressant effect of OxyCODONE.  Management: Avoid concomitant use of oxycodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Perampanel: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Piribedil: CNS Depressants may enhance the CNS depressant effect of Piribedil. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Procarbazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ropeginterferon Alfa-2b: CNS Depressants may enhance the adverse/toxic effect of Ropeginterferon Alfa-2b. Specifically, the risk of neuropsychiatric adverse effects may be increased.  Management: Avoid coadministration of ropeginterferon alfa-2b and other CNS depressants. If this combination cannot be avoided, monitor patients for neuropsychiatric adverse effects (eg, depression, suicidal ideation, aggression, mania).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rufinamide: May enhance the adverse/toxic effect of CNS Depressants. Specifically, sleepiness and dizziness may be enhanced.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Suvorexant: CNS Depressants may enhance the CNS depressant effect of Suvorexant.  Management: Dose reduction of suvorexant and/or any other CNS depressant may be necessary.  Use of suvorexant with alcohol is not recommended, and the use of suvorexant with any other drug to treat insomnia is not recommended.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thalidomide: CNS Depressants may enhance the CNS depressant effect of Thalidomide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Trimeprazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Valerian: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem adult dose to 1.75 mg for  men who are also receiving other CNS depressants. No such dose change is recommended for women. Avoid use with other CNS depressants at bedtime; avoid use with alcohol.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zuranolone: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to the use of zuranolone with other CNS depressants or alcohol. If combined, consider a zuranolone dose reduction and monitor patients closely for increased CNS depressant effects.<i> Risk D: Consider therapy modification</i></p></div>
<div class="block foi drugH1Div" id="F54018729"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;display:inline">The C<sub>max</sub> and AUC<sub>0-∞</sub> were increased by 59% and 29%, respectively, when administered with a high-calorie, high-fat meal (compared to fasting). Management: Administer avapritinib at least 1 hour before or 2 hours after a meal.</p></div>
<div class="block rep_considerations drugH1Div" id="F54018725"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Evaluate pregnancy status prior to use; verify the patient is not pregnant prior to treatment initiation in patients who could become pregnant. Patients who could become pregnant and patients with partners who could become pregnant should use effective contraception during therapy and for 6 weeks after the last dose of avapritinib.</p>
<p style="text-indent:0em;margin-top:2em;">Based on data from animal studies, avapritinib 200 mg and 300 mg doses may impair fertility.</p></div>
<div class="block pri drugH1Div" id="F54018724"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Based on the mechanism of action and data from animal reproduction studies, in utero exposure to avapritinib may cause fetal harm.</p></div>
<div class="block brc drugH1Div" id="F54018726"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if avapritinib is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">Due to the potential for serious adverse reactions in the breastfed infant, breastfeeding is not recommended by the manufacturer during treatment and for 2 weeks after the last avapritinib dose.</p></div>
<div class="block mop drugH1Div" id="F54018747"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">Assess PDGFRA exon 18 mutation status for use in patients with gastrointestinal stromal tumor (GIST). For advanced systemic mastocytosis, obtain a platelet count prior to therapy initiation, then every 2 weeks for the first 8 weeks (regardless of baseline platelet count). After 8 weeks of therapy, monitor platelet count every 2 weeks (or more frequently if clinically necessary) if platelets are &lt;75,000/mm<sup>3</sup>, every 4 weeks if platelets are 75,000 to 100,000/mm<sup>3</sup>, and as clinically necessary if platelets are &gt;100,000/mm<sup>3</sup>. Verify pregnancy status prior to use in patients who could become pregnant. Assess for risk factors for intracranial hemorrhage (history of vascular aneurysm, recent intracranial hemorrhage or cerebrovascular accident [within the prior year], concomitant use of anticoagulants, or thrombocytopenia) prior to treatment. Monitor for cognitive effects (eg, memory impairment, confusion, amnesia, sleep/speech disorders) and for signs/symptoms of intracranial hemorrhage (particularly in patients with risk factors) and assess promptly if symptoms (headache, nausea/vomiting, vision changes, altered mental status) occur. Monitor adherence.</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">The American Society of Clinical Oncology hepatitis B virus (HBV) screening and management provisional clinical opinion (ASCO [Hwang 2020]) recommends HBV screening with hepatitis B surface antigen, hepatitis B core antibody, total Ig or IgG, and antibody to hepatitis B surface antigen prior to beginning (or at the beginning of) systemic anticancer therapy; do not delay treatment for screening/results. Detection of chronic or past HBV infection requires a risk assessment to determine antiviral prophylaxis requirements, monitoring, and follow-up.</p></div>
<div class="block pha drugH1Div" id="F54018732"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Avapritinib is a potent tyrosine kinase inhibitor that blocks PDGFRA and KIT D816V; it targets PDGFRA and PDGFR D842 mutants, as well as KIT exon 11, 11/17, and 17 mutants. Certain PDGFRA and KIT mutations may result in autophosphorylation and constitutive activation of these receptors, which may contribute to tumor and mast cell proliferation. Avapritinib inhibits autophosphorylation of KIT D816V and PDGFRA D842V, which are mutations associated with resistance to approved kinase inhibitors.</p></div>
<div class="block phk drugH1Div" id="F54018733"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> Pharmacokinetic data obtained following a 300 mg dose for gastrointestinal stromal tumor (GIST), 200 mg dose for advanced systemic mastocytosis (AdvSM), and 25 mg dose for indolent systemic mastocytosis (ISM).</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: GIST: 1,310 L; AdvSM: 1,900 L; ISM: 1,400 L.</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: 98.8%.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Primarily hepatic via CYP3A4 and CYP3A5 (major) and CYP2C9 (minor); the formation of the glucuronide metabolite (M690) is primarily catalyzed by UGT1A3.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: GIST: 32 to 57 hours; AdvSM: 20 to 39 hours; ISM: 38 to 45 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak: 2 to 4 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Feces: 70% (11% as unchanged drug); urine: 18% (&lt;1% as unchanged drug).</p>
<p style="text-indent:-2em;margin-left:4em;">Clearance: GIST: 21.8 L/hour; AdvSM: 40.3 L/hour; ISM: 21.6 L/hour.</p></div>
<div class="block phksp drugH1Div" id="F58280767"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:0em;display:inline">Hepatic function impairment: Unbound AUC<sub>0-INF </sub>was 61% higher in subjects with severe impairment (Child-Pugh class C), compared to matched healthy subjects with normal hepatic function.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F56522012"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Ayvakyt</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Ayvakyt</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Ayvakyt</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Ayvakyt</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Ayvakyt</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Ayvakyt</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Ayvakit</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Ayvakyt</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Ayvakit</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Ayvakyt</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-USP.1">
<a name="USP.1"></a>&lt;800&gt; Hazardous Drugs—Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary </i>(USP 43-NF 38). Rockville, MD: United States Pharmacopeia Convention; 2020:74-92.</div>
</li>
<li>
<div class="reference">
                  Ayvakit (avapritinib) [prescribing information]. Cambridge, MA: Blueprint Medicines Corporation; May 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32821296">
<a name="32821296"></a>Cocorocchio E, Pala L, Conforti F, Guerini-Rocco E, De Pas T, Ferrucci PF. Successful treatment with avapritinib in patient with mucosal metastatic melanoma. <i>Ther Adv Med Oncol</i>. 2020;12:1758835920946158. doi:10.1177/1758835920946158<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/avapritinib-drug-information/abstract-text/32821296/pubmed" id="32821296" target="_blank">32821296</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34873347">
<a name="34873347"></a>DeAngelo DJ, Radia DH, George TI, et al. Safety and efficacy of avapritinib in advanced systemic mastocytosis: the phase 1 EXPLORER trial. <i>Nat Med</i>. 2021;27(12):2183-2191. doi:10.1038/s41591-021-01538-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/avapritinib-drug-information/abstract-text/34873347/pubmed" id="34873347" target="_blank">34873347</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32100250">
<a name="32100250"></a>Dhillon S. Avapritinib: First approval. <i>Drugs</i>. 2020;80(4):433-439. doi:10.1007/s40265-020-01275-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/avapritinib-drug-information/abstract-text/32100250/pubmed" id="32100250" target="_blank">32100250</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31033566">
<a name="31033566"></a>Falkenhorst J, Hamacher R, Bauer S. New therapeutic agents in gastrointestinal stromal tumours. <i>Curr Opin Oncol</i>. 2019;31(4):322-328. doi:10.1097/CCO.0000000000000549<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/avapritinib-drug-information/abstract-text/31033566/pubmed" id="31033566" target="_blank">31033566</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32462367">
<a name="32462367"></a>Farag S, Smith MJ, Fotiadis N, Constantinidou A, Jones RL. Revolutions in treatment options in gastrointestinal stromal tumours (GISTs): the latest updates. <i>Curr Treat Options Oncol</i>. 2020;21(7):55. doi:10.1007/s11864-020-00754-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/avapritinib-drug-information/abstract-text/32462367/pubmed" id="32462367" target="_blank">32462367</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34282744">
<a name="34282744"></a>García Caride S, Marquina G, Díaz Valle D. Preseptal cellulitis, intraocular inflammatory reaction and corneal persistent epithelial defect as side effects of avapritinib. <i>Anticancer Drugs</i>. 2021;32(10):1127-1130. doi:10.1097/CAD.0000000000001123<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/avapritinib-drug-information/abstract-text/34282744/pubmed" id="34282744" target="_blank">34282744</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31372066">
<a name="31372066"></a>Gilreath JA, Tchertanov L, Deininger MW. Novel approaches to treating advanced systemic mastocytosis. <i>Clin Pharmacol</i>. 2019;11:77-92. doi:10.2147/CPAA.S206615<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/avapritinib-drug-information/abstract-text/31372066/pubmed" id="31372066" target="_blank">31372066</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34873345">
<a name="34873345"></a>Gotlib J, Reiter A, Radia DH, et al. Efficacy and safety of avapritinib in advanced systemic mastocytosis: interim analysis of the phase 2 PATHFINDER trial. <i>Nat Med</i>. 2021;27(12):2192-2199. doi:10.1038/s41591-021-01539-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/avapritinib-drug-information/abstract-text/34873345/pubmed" id="34873345" target="_blank">34873345</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32615108">
<a name="32615108"></a>Heinrich MC, Jones RL, von Mehren M, et al. Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trial. <i>Lancet Oncol.</i> 2020;21(7):935-946. doi:10.1016/S1470-2045(20)30269-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/avapritinib-drug-information/abstract-text/32615108/pubmed" id="32615108" target="_blank">32615108</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32658626">
<a name="32658626"></a>Hesketh PJ, Kris MG, Basch E, et al. Antiemetics: ASCO guideline update. <i>J Clin Oncol</i>. 2020;38(24):2782-2797. doi:10.1200/JCO.20.01296<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/avapritinib-drug-information/abstract-text/32658626/pubmed" id="32658626" target="_blank">32658626</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32716741">
<a name="32716741"></a>Hwang JP, Feld JJ, Hammond SP, et al. Hepatitis B virus screening and management for patients with cancer prior to therapy: ASCO provisional clinical opinion update. <i>J Clin Oncol</i>. 2020;38(31):3698-3715. doi:10.1200/JCO.20.01757<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/avapritinib-drug-information/abstract-text/32716741/pubmed" id="32716741" target="_blank">32716741</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9024461">
<a name="9024461"></a>"Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics (AAP) Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278. doi:10.1542/peds.99.2.268<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/avapritinib-drug-information/abstract-text/9024461/pubmed" id="9024461" target="_blank">9024461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32453031">
<a name="32453031"></a>Martin-Broto J, Moura DS. New drugs in gastrointestinal stromal tumors. <i>Curr Opin Oncol</i>. Published online May 20, 2020. doi:10.1097/CCO.0000000000000642<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/avapritinib-drug-information/abstract-text/32453031/pubmed" id="32453031" target="_blank">32453031</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35345498">
<a name="35345498"></a>Mohammed TO, Malik S, Hassan S, Solomon Z, Choi JN. Palpable purpuric eruption mimicking vasculitis following avapritinib. <i>JAAD Case Rep</i>. 2022;22:89-92. doi:10.1016/j.jdcr.2022.01.031<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/avapritinib-drug-information/abstract-text/35345498/pubmed" id="35345498" target="_blank">35345498</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34663404">
<a name="34663404"></a>Padilla B, Shields AL, Taylor F, et al. Psychometric evaluation of the Indolent Systemic Mastocytosis Symptom Assessment Form (ISM-SAF) in a phase 2 clinical study. <i>Orphanet J Rare Dis</i>. 2021;16(1):434. doi:10.1186/s13023-021-02037-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/avapritinib-drug-information/abstract-text/34663404/pubmed" id="34663404" target="_blank">34663404</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NIOSH.1">
<a name="NIOSH.1"></a>US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href="https://www.cdc.gov/niosh/docs/2016-161/" target="_blank">https://www.cdc.gov/niosh/docs/2016-161/</a>. Updated September 2016. Accessed January 13, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17555487">
<a name="17555487"></a>Zar T, Graeber C, Perazella MA. Recognition, treatment, and prevention of propylene glycol toxicity. <i>Semin Dial</i>. 2007;20(3):217-219. doi:10.1111/j.1525-139X.2007.00280.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/avapritinib-drug-information/abstract-text/17555487/pubmed" id="17555487" target="_blank">17555487</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 126556 Version 102.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
